Back
Articles
06/29/2023

IMWG consensus criteria for response and minimal residual disease assessment in Multiple Myeloma - Lancet Oncol. 2016

Shaji Kumar, Bruno Paiva, Kenneth C Anderson, Brian Durie, Ola Landgren, Philippe Moreau, Nikhil Munshi, Sagar Lonial, Joan Bladé, Maria-Victoria Mateos, Meletios Dimopoulos, Efstathios Kastritis, Mario Boccadoro, Robert Orlowski, Hartmut Goldschmidt, Andrew Spencer, Jian Hou, Wee Joo Chng, Saad Z Usmani, Elena Zamagni, Kazuyuki Shimizu, Sundar Jagannath, Hans E Johnsen, Evangelos Terpos, Anthony Reiman, Robert A Kyle, Pieter Sonneveld, Paul G Richardson, Philip McCarthy, Heinz Ludwig, Wenming Chen, Michele Cavo, Jean-Luc Harousseau, Suzanne Lentzsch, Jens Hillengass, Antonio Palumbo, Alberto Orfao, S Vincent Rajkumar, Jesus San Miguel, Herve Avet-Loiseau

Lancet Oncol. 2016 Aug;17(8):e328-e346. DOI: 10.1016/S1470-2045(16)30206-6. PMID: 27511158.
decoration

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in Multiple Myeloma

With the development of new effective treatment with improved depth of responses, new response criteria have been developed to define responses that are deeper than those conventionally defined as complete response. Here are the new response categories of minimal residual disease negativity defined by the IMWG to allow for uniform reporting.

Access the Publication

Access

More articles

View all articles
Articles
06/29/2023

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma - Front Oncol. 2020

Articles
06/29/2023

Extramedullary disease in multiple myeloma: a systematic literature review - Blood Cancer J. 2022

Articles
06/29/2023

Making clinical decisions based on measurable residual disease improves the outcome in Multiple Myeloma - J Hematol Oncol. 2021

Articles
06/08/2023

Mass spectrometry for the evaluation of monoclonal proteins in MM and related disorders - Blood Cancer J. 2021

Articles
06/29/2023

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications - Front Oncol. 2022

Articles
06/29/2023

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration - Clin Cancer Res. 2021

Articles
06/29/2023

Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure! - Journal of Clinical Oncology, 2022

Articles
08/28/2023

Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma - Blood Adv. 2020

Articles
08/28/2023

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma - Cancers 2021